Change in cardiovascular risk after initiation of anti-rheumatic treatment in early rheumatoid arthritis

Sirs,
Ischaemic heart disease and stroke are the most common causes of death and rheumatoid arthritis (RA) is associated with an increased risk of these cardiovascular diseases (CVD) (1-2). Different cardiovascular (CV) risk models are used to estimate the 10-year risk of fatal and non-fatal CVD, and indicate if an antihypertensive and/or statin is necessary to lower the risk for a future CV event (3-4). To determine the influence of the risk model as well as the moment of CV risk screening, CV risk scores were calculated in 104 consecutive early RA patients before and four weeks after treatment with methotrexate escalated to 17.5 mg/week, combined with 30 mg/day prednisolone tapered to 10 mg in four weeks (5). Risk scores were assessed with two calculators, the Dutch Systematic Coronary Risk Evaluation (SCORE) (3) and the HeartSCORE (4).

The correlation between absolute values of the Dutch SCORE and HeartSCORE had a spearmen coefficient of 0.79 with a p-value of 0.01. The agreement between the different risk categories (low, medium, high) was 62.4%, and had a slight correlation (k=0.13, p<0.01) (6). At baseline, 29.9% of the patients were classified as high risk according to the Dutch SCORE and HeartSCORE, respectively. Accordingly to the Dutch CV-risk management guidelines that use the Dutch SCORE, all high risk patients had at baseline an indication for (adaptations of) CV preventive treatment. In our study, many patients were classified in a different category and four patients to a higher category. In the HeartSCORE four (4.1%) patients changed from category. In 13.4% patients the advice for (adaptations of) preventive treatment changed during the first four weeks of anti-rheumatic treatment. If baseline CV risk assessment would be applied, this would lead to potential overtreatment in 10% of all patients. The change in CV risk score and hence the advice about preventive treatment is thus correlated with the reduction of disease activity or the initiation of anti-rheumatic treatment. This is in line with previous literature that, e.g., described a reduction in acute myocardial infarction with the use of methotrexate (RR 0.81) (7-8). Furthermore, risk estimation depends on the risk calculator that is used. Clinically this will have an impact on the therapy and prevention strategies chosen. The difference between the Dutch SCORE and the HeartSCORE is partially explained because the HeartSCORE only assesses the risk on mortality and does not take non-fatal CV events into account (3-4). The influence of fluctuations in disease activity over time in RA patients is difficult to incorporate in risk prediction models; single disease activity measurements (as disease activity score or C-reactive protein) appear not to be adequate (9). Therefore, it is important to realise the limitations of the CV risk calculator.

In conclusion, CV risk management is important early in the course of RA. However, the timing of CV risk assessment, as well as the applied CV risk model, have an impact on the advice regarding the need for (adaptations of) CV preventive treatment. In our study, many patients were classified in a different risk category after the first month of anti-rheumatic treatment, which led in 13% of the patients to a change of the CV preventive treatment advice. It seems wise to perform CV risk assessment early in the course of RA, but not in the phase of active disease. Further research is needed to determine which risk model is optimal and then when in the course of RA it should be applied.

S.A. TURK1
M. HESLINGA1
J. TWISK1
V. VAN DER LUGT1
W.F. LEMS1
D. VAN SCHAARDEGREN1
M.T. NURMOHAMED2

1Amsterdam Rheumatology and Immunology Center / Reade, Amsterdam; 2VU University Medical Center, Department of Epidemiology and Biostatistics, Amsterdam; 3Amsterdam Rheumatology and Immunology Center / VU University Medical Center, Amsterdam; 4Amsterdam Rheumatology and Immunology Center / Academic Medical Center, Amsterdam, the Netherlands.

Competing interests: none declared.

1. URL: http://www.who.int (accessed June 2017).